Divi’s Laboratories’ June-quarter profit, margin miss estimates

Contract Development and Production Organization (CDMO) Divi’s laboratoryies Ltd’s June-ride earnings missed forecasts due to pricing pressure in the generic business.

The income of the drug producer based on Haydarabad increased by 13.7% annually La2.410 crore, net profit increased by 26.7% La545 Crore.

Independently, net profit La557 Crore in the first quarter of 2025-26.

A survey of 18 intermediaries Bloomberg DECREASED THE INCOME La2,462 CRORE AND NET Snow La582.7 Crore.

The company’s END increased by 17.2% every year La729 Crore. The EBITDA margin rose to 29.37% a year ago to a slightly 30.25%. FAVÖK, interest, tax, depreciation and pre -fire department gains.

Brokeres Kotak Securities and Nuvama fixed the EBITDA margin of the company, which would increase to 33-34% in the examined quarter.

The generic business produced 47% of its overall income and produced the rest of the special synthesis.

Divi produces medicine for generic players and innovators. Special synthesis refers to the production of specific chemical compounds such as new APIs or intermediates adapted to the needs of a customer. APIs are the basic components of a drug responsible for making treatment effective.

Pricing pressure

Permanent pricing pressure in global markets affected the US generic pharmaceutical producers and focused on Divi. However, the company’s management said that investors under a call for earnings on Wednesday continued to be flexible due to the strong backward integration of the company.

The company’s management, Divi’nin global innovators also attracted the increasing interest, he said. Innovators are looking at Derisk and diversifying supply chains away from China, while Indian CDMO giants like Divi’s are preparing to win. The company saw a stable increase in proposal requests.

In the last quarter of 2024-25, the company announced a long-term production and supply agreement with a leading global pharmaceutical company. La650-750 Crore. In January, the 3rd unit of the Kakinada facility began commercial operations.

This year, the company plans to carry out three Capex programs with an estimated expenditure. LaThe Chairman of the Executive Board Kiran Divi told investors 2,000 Crore.

Divi’s laboratories shares LaOn Wednesday, 6.183 at the National Stock Exchange, the company’s earnings fell 3.53% as he missed forecasts.